A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Arcus Biosciences, Inc.

Criteria

Inclusion Criteria:

• 18 to 55 years, inclusive, at screening

• Body mass index 19 to 30 kg/m2

• Willing and able to sign informed consent

• Negative tests for hepatitis B surface antigen, anti-hepatitis C virus, and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening

• Healthy as determined by pre-study screening

Exclusion Criteria:

• History of clinically significant drug and/or food allergies

• Positive drug and alcohol screen at screening and (each) admission to the clinical research center.

• Participation in a drug study within 60 days prior to (the first) drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to (the first) drug administration in the current study

• Participants who have significant infection or known inflammatory process on screening or admission